← Back to Home

Enabling Joint Cells to Repair on Demand: WashU Receives $17 Million to Advance Osteoarthritis Gene Therapy

Nanoparticles deliver gene constructs into joints, enabling cells to produce repair proteins when disease signals appear. After reaching animal-study milestones, the therapy has received new funding, with the team aiming to begin human trials in about 18 months.

By SURL BioNews

The pain and limited mobility caused by osteoarthritis stem from progressively damaged joint tissues. If joint cells could sense inflammation and produce repair proteins themselves when needed, treatment might be able to intervene further in the disease process. Washington University School of Medicine in St. Louis (WashU Medicine) is developing an injectable gene therapy along these lines and announced on October 14 that it had received $17 million to support development before human trials.

The funding comes from the U.S. Advanced Research Projects Agency for Health (ARPA-H) and is part of Phase 2.1 of NITRO, its osteoarthritis tissue regeneration program. The university said the team had met the previous phase’s animal-model milestones, demonstrating that damaged tissue could be encouraged to regenerate without surgery. “Phase 2.1” here refers to a program funding phase, not an indication that the therapy has entered a Phase 2 clinical trial.

The team, jointly led by Farshid Guilak and Christine Pham, uses nanoparticles to deliver engineered gene constructs directly into the knee joint. Once joint tissue cells take up these constructs, they can respond to signals such as inflammation or excessive mechanical loading by initiating the production of proteins that promote tissue repair and growth.

Another key feature of the design is that protein output adjusts to disease signals: when the signals subside, production stops. The researchers hope this will prevent sustained overproduction of repair proteins and align the treatment’s effects more closely with the joint’s needs at any given time. Whether this regulation can be maintained over the long term in humans remains to be verified.

The new funding will support the team’s collaboration with CRISPR Therapeutics and SynGenix to complete further testing and commercial development. SynGenix is a WashU startup founded by Guilak and Pham to advance the translation of this technology. Under the university’s current plans, human clinical trials are expected to begin in about 18 months, but the announcement has not yet provided the trial size, participant eligibility criteria, or specific methods for evaluating efficacy.

The animal research provides a basis for moving forward, but it cannot yet establish how much patients might benefit. The announcement did not disclose the animal studies’ sample sizes, follow-up duration, or complete quantitative results. The versions published by the university’s news website, The Source, and by Newswise also derive from the same university announcement and cannot be regarded as independent validation of efficacy.

The team ultimately hopes to achieve once-yearly injections that allow joint tissues to retain the ability to respond to disease signals. This remains a development goal. As the work moves from animal models to patients, the questions that must be clarified next are how long the repair effects can last, whether the treatment can improve pain and physical function, and the long-term safety of gene delivery and protein regulation.

References

  1. WashU Medicine
  2. The Source – Washington University in St. Louis
  3. Newswise – Washington University in St. Louis